Survival in Patients with Cirrhosis According to Etiology. Retrospective Cohort

Authors

DOI:

https://doi.org/10.22516/25007440.703

Keywords:

Survival, Fatty Liver, Non-Alcoholic Fatty Liver Disease, Liver cirrhosis

Abstract

Introduction: Cirrhosis is the final stage of chronically progressive liver diseases of various etiologies. It is a common disease, with a variable prevalence in each country. Its peak incidence occurs between 40 and 50 years of age, predominantly in men.

Aims: To compare a cohort of patients diagnosed with cirrhosis, evaluate their complications and survival according to etiology, describe clinical and laboratory aspects, and determine the role of a fatty liver.

Materials and methods: A retrospective cohort study was carried out with patients who held a specialized hepatology consultation in the center of liver and digestive diseases (CEHYD) in Bogotá, Colombia, between January 2010 and June 2019.

Results: We reviewed a total of 1,200 medical records (56.8 % women). There were no statistically significant differences in median survival between groups by etiology, sex, presence or absence of complications, or Child. We noted that the older the age at the diagnosis of cirrhosis, the higher the risk of death; HR 1.04 (95 % CI 1.02-1.075). For each month that follow-up increases, the risk of death decreases by 90 %; HR 0.1 (95 % CI 0.03-0.29). For each month that the follow-up of complications increases, the risk of death is reduced by 2 %; HR 0.98 (95 % CI 0.97-0.99).

Conclusions: Survival by etiology was similar in the different groups. Nonalcoholic steatohepatitis (NASH) was the leading cause of cirrhosis in this cohort. Efforts should focus on its diagnosis and management in the early stages.

Downloads

Download data is not yet available.

Author Biographies

Jhon Edison Prieto-Ortiz, Centro de enfermedades hepáticas y digestivas - CEHYD

Médico Cirujano, especialista en Medicina interna, Gastroenterología y Endoscopia Digestiva, Hepatología y transplante hepático. Bogotá, Colombia.

 

Nathaly Garzón Orjuela, Universidad Nacional de Colombia

Magister en Epidemiologia clínica, Universidad Nacional y miembro del grupo de investigación Equidad y salud. Bogotá, Colombia.

Santiago Sánchez-Pardo, Universidad Industrial de Santander

Médico Cirujano, especialista en Medicina interna, Universidad Industrial de Santander. Bucaramanga, Colombia.

Robin Germán Prieto-Ortíz, Centro de enfermedades hepáticas y digestivas - CEHYD SAS.

Gastroenterólogo. Especialista en Cirugía General, Gastroenterología y Endoscopia Digestiva. Hospital Central de la Policía (HOCEN). Bogotá, Colombia.

Javier Eslava Schmalbach, Universidad Nacional de Colombia

Médico, Profesor del departamento de Cirugía. Bogotá, Colombia.

References

Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014;383(9930):1749-61. https://doi.org/10.1016/S0140-6736(14)60121-5

Lefton HB, Rosa A, Cohen M. Diagnosis and epidemiology of cirrhosis. Med Clin North Am. 2009;93(4):787-99. https://doi.org/10.1016/j.mcna.2009.03.002

Hatzakis A, Wait S, Bruix J, Buti M, Carballo M, Cavaleri M, et al. The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference. J Viral Hepat. 2011:18(Suppl 1):1-16. https://doi.org/10.1111/j.1365-2893.2011.01499.x

Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol. 1978;31(5):395-414. https://doi.org/10.1136/jcp.31.5.395

Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011;25(2):195-206. https://doi.org/10.1016/j.bpg.2011.02.005

Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655-69. https://doi.org/10.1053/j.gastro.2008.03.003

García-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology. 2010;51(4):1445-9. https://doi.org/10.1002/hep.23478

Desmet VS, Roskams T. Cirrhosis reversal: A duel between dogma and myth. J Hepatol. 2004;40(5):860-7. https://doi.org/10.1016/j.jhep.2004.03.007

Friedman SL, Bansal MB. Reversal of hepatic fibrosis-fact or fantasy? Hepatology. 2006;43(2 Suppl 1):S82-8. https://doi.org/10.1002/hep.20974

Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: A prospective study on the incidence and hierarchy of major complications. Gut. 2004;53(5):744-9. https://doi.org/10.1136/gut.2003.020263

Asrani SK, Kamath PS. Natural history of cirrhosis. Curr Gastroenterol Rep. 2013;15(2):308. https://doi.org/10.1007/s11894-012-0308-y

D’Amico G, García-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 2006;44(1):217-31. https://doi.org/10.1016/j.jhep.2005.10.013

Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-51. https://doi.org/10.1016/S0140-6736(08)60383-9

D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis. 1999;19(4):475-505. https://doi.org/10.1055/s-2007-1007133

Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: Evidence based treatment. World J Gastroenterol. 2014;20(18):5442-60. https://doi.org/10.3748/wjg.v20.i18.5442

Starr SP, Raines D. Cirrhosis: Diagnosis, management, and prevention. Am Fam Physician. 2011;84(12):1353-9.

Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94(2):153-6. https://doi.org/10.1002/ijc.1440

Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42(5):1208-36. https://doi.org/10.1002/hep.20933

White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342-1359.e2. https://doi.org/10.1016/j.cgh.2012.10.001

Bruix J. Hepatocellular carcinoma: Paving the road for further developments. Semin Liver Dis. 2014;34(4):361. https://doi.org/10.1055/s-0034-1395181

Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5(1):52-8. https://doi.org/10.4239/wjd.v5.i1.52

Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33(6):1358-64. https://doi.org/10.1053/jhep.2001.24432

Haga Y, Kanda T, Sasaki R, Nakamura M, Nakamoto S, Yokosuka O. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. World J Gastroenterol. 2015;21(46):12989-95. https://doi.org/10.3748/wjg.v21.i46.12989

Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-70. https://doi.org/10.1053/jhep.2001.22172

Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375-82.e.2. https://doi.org/10.1053/j.gastro.2013.04.005

Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10-year population-based study, Aliment Pharmacol Ther. 2016;43(12):1330-9. https://doi.org/10.1111/apt.13635

Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, etiology and mortality of cirrhosis: A population-based cohort study. Scand J Gastroenterol. 2012;47(6):702-9. https://doi.org/10.3109/00365521.2012.661759

D’Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31(5):468-75. https://doi.org/10.1007/BF01320309

D’Amico G. Natural history of compensated cirrhosis and varices. En: Boyer TD, Groszmann RJ (editores). Complications of cirrhosis: pathogenesis, consequences and therapy. VA: American Association for the Study of Liver Diseases; 2001. p. 118-23.

Rodríguez-Osorio I, Mena A, Meijide H, Morano L, Delgado M, Cid P, et al. Liver related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. PLoS One. 2019;14(6):e0217052. https://doi.org/10.1371/journal.pone.0217052

Wang X, Lin SX, Tao J, Wei XQ, Liu YT, Chen YM, et al. Study of liver cirrhosis over ten consecutive years in Southern China. World J Gastroenterol. 2014;20(37):13546-55. https://doi.org/10.3748/wjg.v20.i37.13546

Orman ES, Roberts A, Ghabril M, Nephew L, Desai A, Patidar K, et al. Trends in characteristics, mortality, and other outcomes of patients with newly diagnosed cirrhosis. JAMA Netw Open. 2019;5;2(6):e196412. https://doi.org/10.1001/jamanetworkopen.2019.6412

Giraldo AM, Barraza M, Villa H, Martínez JW, García G. Caracterización epidemiológica de pacientes con cirrosis en una consulta de gastroenterología en Pereira, Colombia, 2009-2012. Rev Med Risaralda. 2014;20(2):86-94.

Prieto JE, Sánchez S, Prieto RG, Rojas E, González L, Mendivelso F. Características clínicas y descompensación en pacientes con cirrosis hepática atendidos en dos centros de hepatología en la ciudad de Bogotá D.C., 2010-2014. Rev Col Gastroenterol. 2016;31(1):1-8. https://doi.org/10.22516/25007440.66.

Escorcia Charris E, Marrugo Balceiro W. Caracterización epidemiológica y clínica de la cirrosis hepática en un centro regional del caribe colombiano: clínica general del norte. Enero 2012 a marzo 2017. Bioc. 2018;13(1):17-30. https://doi.org/10.18041/2390-0512/bioc..1.2242

Debes JD, Chan J, Balderramo D, Kikuchi L, Gonzalez E, Prieto JE, et al. Hepatocellular carcinoma in South America: Evaluation of risk factors, demographics and therapy. Liver International. 2018;38(1):136-43. https://doi.org/10.1111/liv.13502

Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis. Hepatology. 2019;70(4):1119-33. https://doi.org/10.1002/hep.30702

Younossi ZM, Golabi P, de Avila L, Paik JM, Srishord M, Fukui N, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793-801. https://doi.org/10.1016/j.jhep.2019.06.021

Figura 1. Curvas de supervivencias por etiología de cirrosis - Kaplan Meier.

Published

2022-03-15

How to Cite

Prieto-Ortiz, J. E., Garzón Orjuela, N. ., Sánchez-Pardo, S., Prieto-Ortíz, R. G., & Eslava Schmalbach, . J. . (2022). Survival in Patients with Cirrhosis According to Etiology. Retrospective Cohort. Revista Colombiana De Gastroenterología, 37(1), 24–32. https://doi.org/10.22516/25007440.703

Issue

Section

Originals articles

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code

Some similar items: